Shoji Hiroshi, Sakamoto Ryosuke, Saito Chisato, Akino Kozo, Taniguchi Masahiko
Division of Neurology, St. Mary's Hospital, Kurume, Fukuoka, Japan.
A member of the House of Councilors, Tokyo Office, Japan.
Intractable Rare Dis Res. 2023 Aug;12(3):198-201. doi: 10.5582/irdr.2023.01051.
Hereditary motor and sensory neuropathy with proximal dominant involvement (HMSN-P) is an intractable neurological disease with autosomal dominant inheritance, four-limb weakness, sensory impairment, and a slowly progressive course. HMSN-P patients develop four-limb paralysis at the advanced-stage, as in amyotrophic lateral sclerosis (ALS). There is a natural 20- to 30-year course from initial painful muscle cramps and four-limb paralysis to respiratory dysfunction. A delay in the diagnosis of HMSN-P occurs due to the 20- to 30-year span from the initial symptom(s) to typical quadriplegia. Its early diagnosis is important, but the involvement of painful muscle cramps as an early symptom has not been clear. Following our earlier survey, we conducted a re-survey focusing on painful muscle cramps, assistive-device use, and hope for specific therapies in 16 Japanese patients with advanced-stage HMSN-P. Fifteen patients presented painful muscle cramps as the initial symptom, and muscle cramps in the lower abdomen including the flank were described by 10 of the patients. The presence of painful muscle cramps including those in the abdominal region may be a clue for the early diagnosis of HMSN-P. Painful abdominal cramps have not described in related diseases, , ALS, spinal muscular atrophy, and Charcot-Marie-Tooth disease. Recent patient-welfare improvements and advances in assistive devices including robot-suit assistive limbs are delaying the terminal state of HMSN-P. Regarding specific therapies for HMSN-P, many patients choose both nucleic acid medicine and the application of induced pluripotent stem cells as a specific therapy for HMSN-P.
遗传性运动和感觉神经病伴近端优势受累(HMSN-P)是一种具有常染色体显性遗传的难治性神经疾病,表现为四肢无力、感觉障碍且病程呈缓慢进展。HMSN-P患者在疾病晚期会出现四肢瘫痪,类似于肌萎缩侧索硬化症(ALS)。从最初的疼痛性肌肉痉挛和四肢瘫痪发展到呼吸功能障碍,自然病程为20至30年。由于从最初症状到典型四肢瘫痪的时间跨度为20至30年,HMSN-P的诊断会出现延迟。其早期诊断很重要,但疼痛性肌肉痉挛作为早期症状的情况尚不清楚。继我们之前的调查之后,我们针对16例晚期HMSN-P日本患者,重点围绕疼痛性肌肉痉挛、辅助设备使用情况以及对特定治疗方法的期望进行了重新调查。15例患者将疼痛性肌肉痉挛作为初始症状,其中10例患者描述了包括侧腹在内的下腹部肌肉痉挛。包括腹部区域在内的疼痛性肌肉痉挛的存在可能是HMSN-P早期诊断的线索。相关疾病如ALS、脊髓性肌萎缩症和夏科-马里-图斯病中均未描述过疼痛性腹部痉挛。近期患者福利的改善以及包括机器人套装辅助肢体在内的辅助设备的进步正在延缓HMSN-P的终末期。关于HMSN-P的特定治疗方法,许多患者选择核酸药物和诱导多能干细胞的应用作为HMSN-P的特定治疗方法。